LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
| Autor: | Passaro, A., Cho, B.C., Wang, Y., Melosky, B., Califano, R., Lee, S-H., Girard, N., Reckamp, K.L., Takahashi, T., Felip, E., Gentzler, R.D., Popat, S., Nassib William Junior, W., Sun, T., Shah, S., Diorio, B., Knoblauch, R.E., Bauml, J.M., García-Campelo, M.R., Wang, J. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S1307-S1307 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|